Syncromune® Presents Multi-Modal Efficacy Assessment Framework at Inaugural Gustave Roussy Intratumoral Immunotherapy SymposiumFORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, June 16, 2026 (GLOBE NEWSWIRE) -- Syncromune, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T™, an investigational in situ multi-target immunotherapy platform for solid tumors, today announced that Executive Chairman and...